Related Experiment Video
Updated: Aug 22, 2026

High Content Screening in Neurodegenerative Diseases
Published on: January 6, 2012
Neurodegenerative disorders--4th annual SMi conference
1Thomson Scientific, Middlesex House, 34-42 Cleveland Street, London, W1T 4JE, UK. tom.phillips@thomson.com
Abstract:
The prevalence of neurodegenerative diseases in the Western World and Japan is predicted to increase sharply as a consequence of the rapidly aging population. To discuss the development of therapeutics in this increasingly important field, the 2-day Neurodegenerative Disorders SMi meeting once again brought together delegates from both large pharmaceutical companies and smaller technology and analysis companies. The majority of presentations focused on Alzheimer's disease, one of the gravest of such conditions that affects approximately half of all people aged 90 years, and on Parkinson's disease. As well as disclosing new therapeutic targets and preclinical and clinical data for drugs in development, several presentations discussed the development of surrogate markers and imaging techniques to monitor disease progression and therapeutic efficacy.
Related Concept Videos
Alzheimer's Disease: Treatment
Alzheimer Disease l: Introduction
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Parkinson's Disease: Overview
Parkinson Disease ll: Pathophysiology
Brain Imaging
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic Stimulation (TMS).

